1) "Xinjiang Daily" Uighur version
《新疆日报》维吾尔文版
1.
In this paper, based on journalism, communications, newspaper editors and other related theoretical study, using field surveys, data analysis, case studies, comparative analysis of the sample analysis methods, "Xinjiang Daily" Uighur version of the comprehensive analysis of the status quo and for further Related newspaper made good suggestions.
《新疆日报》维吾尔文版改革开放30多年来,在办报理念、编辑思想、报道内容、报道方式、经营管理模式、人员结构等方面发生了很大的变化和改善。
3) Xinjiang Uigur population
新疆维吾尔族
1.
To investigate the serum adiponectin concentration and its relation with body mass index(BMI),blood pressure,lipid profile and insulin resistance index in Xinjiang Uigur population.
为探讨正常新疆维吾尔族血清脂联素水平,分析其与与体重指数、血压、血脂代谢及胰岛素抵抗指数间的相关性,本研究收集无血缘关系的新疆维吾尔族正常人164例血清样本,采用酶联免疫法测定血浆脂联素水平,用放射免疫法测定血清空腹胰岛素(FINS)水平。
2.
Objective:To investigate the correlation between single nucleotide polymorphisms(SNP45 and SNP276) of adiponectin gene and type 2 diabetes in XinJiang Uigur Population.
本研究主要通过检测脂联素基因第二外显子第45位及第二内含子276位点多态性的分布,检测基因多态性与血清脂联素水平之间的相关性,探讨脂联素基因第二外显子第45位及第二内含子第276位点多态性与新疆维吾尔族2型糖尿病遗传易感性的关系。
4) Xinjiang Uygur
新疆维吾尔族
1.
Analysis of HLA-B Locus Gene Polymorphism in Sichuan Yi Ethnic Group and Xinjiang Uygur Ethnic Group;
四川彝族和新疆维吾尔族HLA-B基因座基因多态性分析
2.
Objective: To discuss the clinical presentations and prognosis changes in Xinjiang Uygur patients with HIV whose CCR5-Δ32, CCR2-64I and SDF1-3′A genes happen mutations.
目的:探讨新疆维吾尔族艾滋病患者CCR5-Δ32,CCR2-64I及SDF1-3′A基因突变后的临床表现和预后变化。
6) Xinjiang Uygur Autonomous Region
新疆维吾尔自治区
1.
Analysis on the Changing Trend of Pharmaceutical Expenditure of Xinjiang Uygur Autonomous Region From 1995 to 2005 and Correlative Policy;
新疆维吾尔自治区1995—2005年药品费用变化趋势及相关政策分析
2.
Xinjiang Uygur Autonomous Region s Exercise of the Minority Nationalities Regional Autonomy;
新疆维吾尔自治区民族区域自治实践研究
3.
Analysis of the Published Medicine Papers in Xinjiang Uygur Autonomous Region from 1994 to 2005;
新疆维吾尔自治区1994-2005年发表医药卫生科技论文分析
补充资料：[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式：C16H16ClN3O3S
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条